肿瘤免疫疗法，特别是免疫检查点抑制剂（ICIs）已应用于临床，但免疫疗法的低反应仍然是一个棘手的问题。溶瘤病毒（OV）被认为有望用于癌症治疗，因为它们可以选择性地靶向并破坏肿瘤细胞，然后扩散到附近的肿瘤组织进行新一轮的感染。免疫原性细胞死亡（ICD）是OVs抗癌作用的主要机制，是由病毒感染后内质网应激和活性氧超载诱导的，并在不同类型的肿瘤细胞中释放特定的损伤相关分子模式（DAMPs）以达到抗癌目的。将肿瘤微环境从“冷”转变为“热”。在本文中，我们将 ICD 广义地定义为免疫原性的细胞死亡类型，并分别描述了它们的信号通路。我们还重点介绍了 ICD，阐明了近期联合疗法的优缺点及其未来前景。版权所有 © 2024。由 Elsevier B.V. 出版。

Tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has been applied in clinical practice, but low response to immune therapies remains a thorny issue. Oncolytic viruses (OVs) are considered promising for cancer treatment because they can selectively target and destroy tumor cells followed by spreading to nearby tumor tissues for a new round of infection. Immunogenic cell death (ICD), which is the major mechanism of OVs' anticancer effects, is induced by endoplasmic reticulum stress and reactive oxygen species overload after virus infection and release specific damage-associated molecular patterns (DAMPs) in different types of tumor cells to transform the tumor microenvironment from "cold" to "hot". In this paper, we broadly define ICD as those types of cell death that is immunogenic, and describe their signaling pathways respectively. Focusing on ICD, we also elucidate the advantages and disadvantages of recent combination therapies and their future prospects.Copyright © 2024. Published by Elsevier B.V.